Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo
about
Applying the Analytic Hierarchy Process in healthcare research: A systematic literature review and evaluation of reportingDiagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvementHematopoietic stem and progenitor cell harvesting: technical advances and clinical utilityRegulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing.New insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patients.Angiopoietins in haematopoietic stem cell mobilisation in patients with haematological malignanciesPredicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a GruppEarly measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.Successful mobilisation of peripheral blood stem cells in children using plerixafor: a case report and review of the literature.Plerixafor use for peripheral blood stem cell mobilization in KoreaStem cell mobilization in HIV seropositive patients with lymphoma.Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma.Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization.A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program.Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.Circulating hematopoietic progenitors and CD34(+) cells predicted successful hematopoietic stem cell harvest in myeloma and lymphoma patients: experiences from a single institution.Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization.Hematopoietic progenitor cell mobilization for autologous transplantation - a literature review.Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.Multiple myeloma: managing a complex blood cancer.Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma.Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group.New strategies for stem cell mobilization.Intermediate doses of cytarabine plus granulocyte-colony-stimulating factor as an effective and safe regimen for hematopoietic stem cell collection in lymphoma patients with prior mobilization failure.Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.Decision-tree algorithm for optimized hematopoietic progenitor cell-based predictions in peripheral blood stem cell mobilization.Early application of percutaneous vertebroplasty reduces pain without affecting peripheral blood stem cell (PBSC) collection and transplant in newly diagnosed multiple myeloma (MM) patients.UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score.Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF.Plerixafor: what we still have to learn.Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.Recombinant human thrombopoietin improves the efficacy of intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor in mobilizing peripheral blood stem cells in patients with multiple myeloma: A cohort study.Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.Impact of plerixafor (mozobil) on hospital efficiency: A single center experience.Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.
P2860
Q26772051-C858B196-0740-4A77-942C-ABD005A39C87Q27011865-3EF46691-CEBF-44DA-85BA-C947767BB3BDQ27012881-1D9BD21D-03EA-4532-9EFE-10CA294F4C9BQ27692619-12D749C7-3B51-4F7A-A5EC-FFA58FFDFE49Q34114055-2F015BD1-3146-44DF-9F39-E7C02D488CDAQ35049174-4C3544B1-0E38-41D6-AA85-81CBFAD5C54AQ35588325-80ABEE7C-40CD-4F67-A4B5-025BA14D7ED8Q36569033-D33A99C1-02C7-4EDE-8AA5-61A2B5B983F2Q36766494-AEB1E953-2C99-42CC-8F61-6DD65F6DE60EQ36973359-305948E8-A2CE-4A0C-999D-F44E967FAA72Q37273199-80F58402-D6B0-4A9C-BF7E-581CE8B1FFA8Q37432037-10C00DF9-82EC-4AAE-A598-1EFE74EE97A3Q38193590-BB783E5B-15FB-40F2-9952-17D2559C6BD6Q38194916-A72DE07C-8FB9-4AAC-982F-DB2F14EC7468Q38199707-C13DF45A-DAF4-481F-81B3-4515B7DEE1F8Q38200909-6510CBF8-A127-4C18-84B3-E91D5972069EQ38388461-CD1A8949-9F39-474E-B227-8D1EE0AD1434Q38688055-4168E7FF-6AE5-41B8-88DA-386357B2ECCAQ38703298-3C2C1051-46B0-44FA-B617-176ADC0D0EEDQ38771080-59D23EC9-02EF-4691-849B-9441FAE9119CQ38797546-D42F9537-C165-457B-8057-28B4E32297A3Q38951283-8C1051A0-DF19-4096-8590-FEE2F199F125Q39051472-55318C04-68DC-4849-B504-95E6333A1B6BQ41092832-9F854F89-B8E8-488B-8C00-A2A446084811Q41104670-02EA3DDE-CC01-47C5-802A-4203AA59E867Q41685138-3063217F-C7A8-4340-BEF8-4076EA268923Q42380588-231EC07B-18A5-4394-8C5A-1FFD30D85373Q43714381-B9CA101B-9687-4723-81D9-28181122EB25Q44256421-92AB10B8-19CF-4C9A-983D-4C181F74CCE7Q48054177-2D49E9F9-4B3E-4036-B8E0-B75EC335BF03Q48126547-092E89AD-69FA-4023-AAE1-53FBD5C97914Q48251584-8037D254-BFBC-4162-9CCA-046746143D7CQ48251589-C8176E6D-69F6-4C5A-8224-207C990CDBCDQ48336057-9C771C1A-CB35-4862-AAEC-11A99CDDECCCQ48747463-5AD62894-D6E2-4BC1-844D-200633F2752AQ49077951-30E7CC32-CC9C-4629-B5BF-53A938D1F210Q49487144-C91A9E1D-EE78-43F3-B411-5C9933C919B2Q49852695-4E3BB995-F6E9-47BD-BCF8-8C1F869C22C0Q50690379-48CD1A94-8D50-4984-AF6D-19058CF57002Q50703524-CA69FDBA-3D23-4D4B-8CA1-9808B1C40F7F
P2860
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Proposed definition of 'poor m ...... ianoTrapianto di Midollo Osseo
@en
Proposed definition of 'poor m ...... ianoTrapianto di Midollo Osseo
@nl
type
label
Proposed definition of 'poor m ...... ianoTrapianto di Midollo Osseo
@en
Proposed definition of 'poor m ...... ianoTrapianto di Midollo Osseo
@nl
prefLabel
Proposed definition of 'poor m ...... ianoTrapianto di Midollo Osseo
@en
Proposed definition of 'poor m ...... ianoTrapianto di Midollo Osseo
@nl
P2093
P2860
P356
P1476
Proposed definition of 'poor m ...... ianoTrapianto di Midollo Osseo
@en
P2093
A Olivieri
A Rambaldi
Italian Group for Stem Cell Transplantation
M Marchetti
P2860
P2888
P304
P356
10.1038/BMT.2011.82
P407
P577
2011-05-30T00:00:00Z
P5875
P6179
1051547748